Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 2, 2011, Pages 246-257

  Raza, Shahzad ^a   Kornblum, Noah ^b   Kancharla, Venkat P ^a   Baig, Mahadi A ^b   Singh, Amrit B ^a   Kalavar, Madhumati ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Antiangiogenic therapies; Cetuximab; Epidermal growth factor inhibitors; Intensity modulated radiation therapy; Vascular endothelial growth factors

Indexed keywords

ADENOVIRUS VECTOR; AMIFOSTINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DNA VACCINE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; LONAFARNIB; MITOMYCIN C; PACLITAXEL; PEMETREXED; PROTEIN P53; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; HYPOPHARYNX CANCER; INFLAMMATION; INJECTION SITE REACTION; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LARYNX CANCER; LOADING DRUG DOSE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OROPHARYNX CANCER; PRIORITY JOURNAL; RADIATION RESPONSE; RASH; SEPSIS; SKIN MANIFESTATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERRUCA VULGARIS; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; HEAD AND NECK NEOPLASMS; HUMANS; PATENTS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79954470620     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211795328477     Document Type: Article

References (101)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. CA Cancer J Clin 2006; 56: 106-30.
2. Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005; 92: 1341-8.
3. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003; 25: 67-73.
4. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-8.
5. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy In advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
6. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-9.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
8. th, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994; 12: 385-95.
9. Pfister DG, Ang K, Brockstein B, Colevas AD, Ellenhorn J, Goepfert H, et al. NCCN Practice Guidelines for Head and Neck. Cancers Oncology (Williston Park) 2000; 14: 163-94.
10. Yao M, Epstein JB, Modi BJ, Pytynia KB, Mundt AJ, Feldman LE. Current surgical treatment of squamous cell carcinoma of the head and neck. Oral Oncol 2007; 43: 213-23.
11. Harish K. Neck dissections: Radical to conservative. World J Surg Oncol 2005; 3: 21.
12. Ang KK. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol 1998; 8: 230-6.
13. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7-16.
14. Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R, et al. Continuous accelerated 7-days a-week radiotherapy for head-and-neck cancer: Long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006; 66: 706-13.
15. Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial. J Clin Oncol 2006; 24: 2873-8.
16. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 2006; 368: 843-54.
17. Harari, PM, Harris J, Kies MS, Myers JN, Machtay M, Rotman MZ, et al. Phase II randomized trial of surgery followed by chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Int J Radiat Oncol Biol Phys 2007; 69 (Suppl3): S13-S13.
18. Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: Which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60: 1425-39.
19. Kasibhatla M, Kirkpatrick JP, Brizel DM. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2007; 68: 1491-5.
20. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-04.
21. Forastiere AA, Trotti A. Radiotherapy and concurrent chemotherapy: A strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 1999; 91: 2065-6.
22. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 Meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analyses of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-55.
23. Pignon JP, le Maître A, Maillard E, Bourhis J. MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
24. Bourhis J, Armand C, Pignon JP. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 2004; 22 (Suppl; abstr 5505): 489S.
25. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-44.
26. th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Philadelphia, PA, USA (2006).
27. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005; 27: 843-50.
28. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28.
29. Semrau R, Mueller RP, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: Updated results of a randomized multicentrictrial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 64: 1308-16.
30. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704.
31. Glisson BS. The role of docetaxel in the management of squamous cell cancer of the head and neck. Oncology (Williston Park) 2002; 16 (6 Suppl 6): 83-7.
32. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist 2000; 5: 199-208.
33. Bernier J. Alteration of radiotherapy fractionation and concurrent chemotherapy: A new frontier in head and neck oncology? Nat Clin Pract Oncol 2005; 2: 305-14.
34. Ensley J, Crissman J, Kish J, Jacobs J, Weaver A, Kinzie J, et al. The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer 1986; 57: 711-7.
35. Hong WK, Shapshay SM, Bhutani R, Craft ML, Ucmakli A, Yamaguchi KT, et al. Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion. Cancer 1979; 44: 19-25.
36. Leitner SP, Bosl GJ, Strong EW, Gerold FP, Spiro RH, Shah JP, et al. A pilot study of cisplatin-vinblastine as the initial treatment of advanced head and neck cancer. Cancer 1986; 58: 1014-7.
37. Milazzo J, Mohit-Tabatabai MA, Hill GJ, Raina S, Swaminathan A, Cheung NK, et al. Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx. Cancer 1985; 56: 1014-7.
38. Argiris A. Induction chemotherapy for head and neck cancer: Will history repeat itself? J Natl Compr Cancer Netw 2005; 3: 393-403.
39. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multiinstitutional experience. Ann Oncol 2004; 15: 1179-86.
40. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-15.
41. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia GC, Irigoyen A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/ cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2009; 27(suppl; abstr 6009):15s.
42. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8.
43. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006; 24: 2636-43.
44. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341.
45. Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 1994; 29: 243-7.
46. Greene, M. I. Compositions and methods of treating tumors. US7625558 (2009).
47. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2006; 24: 724.
48. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy. J Clin Oncol 2007; 25: 2171-7.
49. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.
50. William WN Jr, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nat Clin Pract Oncol 2009; 6: 132-3.
51. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents. Drugs 2000; 59: 753-67.
52. Tsypin, M., Roder, H., Grigorieva, J. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway. US0231921 (2007).
53. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7.
54. Rao R, Anil K, Bansal L, Dhiman A, Khatri S, Rawat S, et al. Survival benefit and efficacy of gefitinib in recurrent metastatic head and neck cancer. Ind J Med Paed Oncol 2007; 28: 5-10.
55. Chen C, Kane M, Song J, Campana J, Raben A, Hu K, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007; 25: 4880-6.
56. nd ASCO Annual Meeting. Atlanta, GA, USA (2006). J Clin Oncol 2006; 24 (suppl; abstr 5543): 18s.
57. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1: 1398-402.
58. Kondo N, Ishiguro Y, Kimura M, Sano D, Fujita K, Sakakibara A, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep 2008; 20: 373-8.
59. Westheim, R.J.H. Hydrates of erlotinib hydrochloride. US20080167327 (2008).
60. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85.
61. Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, et al. Initial results of a phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 78(4): 1020-5.
62. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-85.
63. Kraut EH, Rhoades C, Zhang Y, Cheng H, Aimiumu J, Chen P, et al. Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Cancer Chemother Pharmacol 2010 May 19 [Epub ahead of print].
64. Kondo N, Tsukuda M, Ishiguro Y, Kimura M, Fujita K, Sakakibara A, et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2010; 23: 957-63.
65. Gillison ML, Glisson BS, O'Leary E, Murphy A, Levine A, Kies SM, et al. Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status. Presented at: 42nd ASCO Annual Meeting. Atlanta, GA, USA (2006), J Clin Oncol 2006; 25(Suppl: abstr 5511):18S.
66. Gilmer, T.M., Greger, G.J., Liu, L., Shi, L. Method of treating cancer using a cMet and AXL inhibitor and an ErbB inhibitor. US20090274693 (2009).
67. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, et al. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-Nhydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem 2010; 53: 2000-9.
68. Razak AR, Siu LL, Le Tourneau C. Molecular targeted therapies in all histologies of head and neck cancers: an update. Curr Opin Oncol 2010; 22: 212-20.
69. Montag M, Dyckhoff G, Lohr J, Helmke BM, Herrmann E, Plinkert PK, et al. Angiogenic growth factors in tissue homogenates of HNSCC: Expression pattern, prognostic relevance, and interrelationships. Cancer Sci 2009; 100: 1210-8.
70. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-57.
71. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73.
72. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28: 21-8.
73. Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010; 28: 677-83.
74. th Annual American Society of Clinical Oncology meeting, J Clin Oncol 2009; 27 (suppl; abstr 6023):15s.
75. Wedge, S. R. Pharmaceutical compositions comprising AZD2171 and ZD6126 and uses thereof. EP1651227 (2008).
76. th Annual American Society of Clinical Onology meeting, J Clin Oncol 2009; 27 (suppl; abstr 6049): 15s.
77. th Annual American Society of Clinical Oncology meeting, J Clin Oncol 2009; 25: (suppl; abstr 6034):15s.
78. th Annual American Society of Clinical Oncology meeting, J Clin Oncol 2008; 26 (suppl; abstr 6034):15s.
79. rd Annual American Society of Clinical Oncology Meeting, J Clin Oncol 2007; 25(suppl; abstr 6044): 15s.
80. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, et al. A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009; 32: 274-9.
81. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 2006; 5: 766-70.
82. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008; 26: 81-7.
83. Gilbert J, Lee J, Argiris A, Feldman LM, Haigentz B, Burtness, et al. Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. Presented at 45th Annual American Society of Clinical Oncology meeting, J Clin Oncol 2009; 27 (suppl; abstr 6020): 15s.
84. Chisholm E, Bapat U, Chisholm C, Alusi G, Vassaux G. Gene therapy in head and neck cancer: A review. Postgrad Med J 2007; 83: 731-7.
85. Kato K, Yamashita R, Matoba R, Monden M, Noguchi S, Takagi T, et al. Cancer gene expression database (CGED): A database for gene expression profiling with accompanying clinical information of human cancer tissues. Nucleic Acids Res 2005; 33: 533-6.
86. Shono T, Tofilon PJ, Schaefer TS, Parikh D, Liu TJ, Lang FF. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 2002; 62: 1069-76.
87. Guse K, Hemminki A. Cancer gene therapy with oncolytic adenoviruses. J BUON 2009; 14 (Suppl 1): S7-15.
88. Parker LP, Wolf JK, Price JE. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. Ann Clin Lab Sci 2000; 30: 395-405.
89. Clayman GL, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-32.
90. Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, et al. Biomarkers predict p53 gene therapy efficacy in recurrent, squamous cell carcinoma of the head and neck. Clin Cancer Res 2009; 15: 7719-25.
91. Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, et al. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMVp53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2009;13: 869-74.
92. Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: Current and future considerations. J Oncol 2009; 2009: 346-345.
93. Victora GD, Socorro-Silva A, Volsi EC, Abdallah K, Lima FD, Smith RB, et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 2009;16: 598-608.
94. Kraeber-Bodéré F, Salaun PY, Oudoux A, Goldenberg DM, Chatal JF, Barbet J. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer 2010; 116: 1118-25.
95. Corry J, Peters LJ, Rischin D. Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol 2010; 11: 287-91.
96. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima(R) in combination with radiotherapy in EGFRpositive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008; 61: 179-88.
97. Uenaka, T., Yamamoto, Y., Matsui, J. Method for assay on the effect of vascularization inhibitor. US20100092490 (2010).
98. van den Broek GB, Wildeman M, Rasch CR, Armstrong N, Schuuring E, Begg AC, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 2009; 124: 2643-50.
99. Röder, H., Tsypin, M., Grigorieva, J. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway. WO2010085235 (2010).
100. Zhu Y.H., Cooper, B.A., Desai, A.J., Wang, J. J-S.J., Doll, J.R., Njoroge, G.F., Girijavallabhan, M.V. Novel farnesyl protein transferase inhibitors as antitumor agents. US7557107 (2009).
101. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 2008; 72: 383-9.